Weilizhibo-B (09887): LBL-024 was used for the first patient in the platinum-resistant ovarian cancer phase IB/II trial

Zhitongcaijing · 2d ago

According to the Zhitong Finance App, Weilizhibo-B (09887) issued an announcement to evaluate that the first patient in the phase IB/II clinical study of opatisumimab (PD-L1/4-1BB bispecific antibody LBL-024) for the treatment of platinum-resistant ovarian cancer has successfully taken medication.

The open-label, multi-center phase IB/II clinical study carried out this time was led by Professor Wu Lingying of the Cancer Hospital of the Chinese Academy of Medical Sciences and is being promoted simultaneously in many hospitals across the country. This trial aims to evaluate the efficacy and safety of opatisumimab combined with paclitaxel in the treatment of platinum-resistant ovarian cancer patients.